Tomas Åslund joins Scandinavian Biopharma as VP Manufacturing

Scandinavian Biopharma continues to expand and strengthen its organization. Tomas Åslund has now started as VP Manufacturing at Scandinavian Biopharma. Tomas has more than 30 years’ experience from the pharmaceutical and life science industry within the field of recombinant protein drugs.

Most recently Tomas worked at Octapharma as Project Manager and Responsible Scientist, leading process validation and process development projects. Tomas has also been Head of Octapharmas Biopharmaceutical production of recombinant FVIII and the responsible manager for a recombinant pilot plant for manufacturing of clinical material.

– Scandinavian Biopharma is a very fast-growing company. To be part of this professional team will be very exciting and I look forward to the journey to develop a new vaccine – ETVAX. With my previous experience of drug development and manufacturing of biologics I hope to add value to make ETVAX^® a vaccine that will save lives in the developing world, but also protect the travelers from tourist diarrhea, says Tomas Åslund, who will be responsible for Manufacturing.

– I’m very pleased to welcome Tomas to Scandinavian Biopharma. Tomas´s solid experience in biological manufacturing fits Scandinavian Biopharma perfectly based on the current phase of the company, says Björn Sjöstrand, CEO Scandinavian Biopharma.

Ämnen

Scandinavian Biopharma

Scandinavian Biopharma is a Swedish research-based biotech company specialist in marketing and sales of vaccines, immunoglobulin’s, biodefense, antidotes and diagnostic tests.

Research and development is mainly focused on development of a new oral traveler’s diarrhea vaccine in collaboration with PATH Vaccine Solutions and University of Gothenburg.

www.scandinavianbiopharma.se

Kontakter

Björn Sjöstrand

Presskontakt VD bjorn@scandinavianbiopharma.se +46 (0)72 712 51 20

Relaterat innehåll

Kyoko Misawa, Clinical study manager at Scandinavian Biopharma

1 Juni 2018 11:07

Kyoko Misawa joins Scandinavian Biopharma as Clinical study manager

Scandinavian Biopharma continues to expand and strengthen its organization. In April Kyoko Misawa started as Clinical Study Manager at Scandinavian Biopharma’s research subsidiary ETVAX AB. Kyoko has more than 20 years’ experience from the pharmaceutical and life science industry in both Japan and Sweden within the field of diabetes, antibiotic, inflammation and orphan drugs

22 Maj 2018 16:14

Scandinavian Biopharma is once again looking back on a highly successful business year

We are very proud to report completion of a large Phase I/II child study in Bangladesh, we were awarded 30 MSEK from Horizon 2020 SME and we kick-started a Phase IIB study on travellers to Benin. We have strengthened our organization and continued to grow our distribution business.

Madelene Franzén, Accounting Manager at Scandinavian Biopharma

5 April 2019 08:53

Scandinavian Biopharma recruits Madelene Franzén as Accounting Manager

Scandinavian Biopharma continues to expand and now welcomes Madelene Franzén as Accounting Manager. Madelene has previously been an authorized accounting consultant and will be responsible for Scandinavian Biopharma's accounts.

Dilek Merdol, head of QC Scandinavian Biopharma

10 Maj 2019 09:53

Scandinavian Biopharma welcomes Dilek Merdol as new head of Quality Control (QC)

Scandinavian Biopharma continues to expand and has now recruited Dilek Merdol as new head of QC. Dilek has a PhD in infectious biology and has 20 years’ experience in R&D and laboratory operations. She comes from a position as manager in the unit of Clinical Microbiology at Karolinska University Laboratory.
“I am looking forward to the challenges and opportunities that this fast-growing co

During last year, the company hit a new sales record for the distribution business. The sales increased from 51,3 MSEK in 2017 to 81,3 MSEK in 2018, representing an increase of 58%!

14 Maj 2019 10:31

Scandinavian Biopharma announces great progress in the development of ETVAX® as well as a strong organic growth for the distribution business

Scandinavian Biopharma can look back on a very successful 2018! The company was granted 7,4 MEUR from EDCTP for testing the protective efficacy of the ETEC vaccine candidate ETVAX® in children below five years of age in Low- and Middle-Income Countries. The distribution business achieved a very strong organic sales growth of 58%.